Director PATIENCE JOHN buys 200,000 AXDX shares at $1.57; stock down -68.9% from 52-week high amid unprofitable fundamentals.
PATIENCE JOHN purchased 200,000 shares at $1.57 on 2024-12-03, increasing holdings by 44.1% from 453.2K to 653.2K shares. The purchase occurs with the stock at $1.57, representing -68.9% from its 52-week high of $5.05 and down -18.6% over the prior 30 days. Accelerate Diagnostics is trading at a market cap of $39.3M with recent quarterly revenue of $3.0M and a net loss of $-14.6M, amid declining annual revenue (-5.4% year-over-year). The director's prior transaction at this ticker (a buy on 2024-01-23) delivered -29.1% return at 30 days and -33.8% at 90 days, establishing a pattern of unfavorable post-purchase price movement. This second purchase at a depressed price level—without material change in underlying financial condition—places capital at significant risk in a company with negative earnings and shrinking revenue.
BDSX Director PATIENCE JOHN buys 75,000 shares at $1.38; cluster buy with 4 others in 14 days as stock down 21.3% in 30 days.
Director John Patience purchased 75,000 shares at $1.38 on 2024-11-05, increasing his holdings to 2,153,298 shares. This transaction is part of a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence among the leadership group. However, context is important: the stock has fallen 21.3% over the past 30 days and 18.9% over 90 days, trading at $26.60 against a 52-week high of $42.40. Patience's own cross-ticker track record shows 1 prior buy with a 90-day win rate of 0.00%, suggesting his past discretionary purchases have not resulted in gains within that timeframe. The company remains unprofitable on a full-year basis despite 28.5% annual revenue growth, creating fundamental uncertainty alongside the recent price pressure.
